Effect of Optimized Immunosuppression (Including Rituximab) on Anti-Donor Alloresponses in Patients With Chronically Rejecting Renal Allografts

RituxiCAN-C4 combined an open-labeled randomized controlled trial (RCT) in 7 UK centers to assess whether rituximab could stabilize kidney function in patients with chronic rejection, with an exploratory analysis of how B cell-depletion influenced T cell anti-donor responses relative to outcome. Bet...

Descripción completa

Detalles Bibliográficos
Autores principales: Shiu, Kin Yee, Stringer, Dominic, McLaughlin, Laura, Shaw, Olivia, Brookes, Paul, Burton, Hannah, Wilkinson, Hannah, Douthwaite, Harriet, Tsui, Tjir-Li, Mclean, Adam, Hilton, Rachel, Griffin, Sian, Geddes, Colin, Ball, Simon, Baker, Richard, Roufosse, Candice, Horsfield, Catherine, Dorling, Anthony
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7012933/
https://www.ncbi.nlm.nih.gov/pubmed/32117242
http://dx.doi.org/10.3389/fimmu.2020.00079

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7012933/
https://www.ncbi.nlm.nih.gov/pubmed/32117242
http://dx.doi.org/10.3389/fimmu.2020.00079

Ejemplares similares